Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1811 vs standard first-line therapy for HER2-mutated advanced or metastatic non-small cell lung cancer
CTR20241861Phase 3Active
- Sponsor
- Hengrui Therapeutics
- Start
- Aug 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of trastuzumab rezetecan in non-small cell lung cancer (NSCLC), sponsored by Hengrui Therapeutics. Started Aug 2024; status: active.
02
Drugs
trastuzumab rezetecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20241861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241861.